COVID-19 Therapeutic Options Under Investigation
Since its emergence in China in December 2019, COVID-19 has quickly spread around the globe causing a pandemic. Vaccination or the development of herd immunity seems the only way to slow down the spread of the virus; however, both are not achievable in the near future. Therefore, effective treatments to mitigate the burden of this pandemic and reduce mortality rates are urgently needed. Preclinical and clinical studies of potential antiviral and immunomodulatory compounds and molecules to identify safe and efficacious therapeutics for COVID-19 are ongoing. Two compounds, remdesivir, and dexamethasone have been so far shown to reduce COVID-19–associated death. Here, we provide a review of the potential therapeutic agents being considered for the treatment and management of COVID-19 patients..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Frontiers in Pharmacology - 11(2020) |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Malak Kaddoura [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Adjunctive therapy |
|---|
| doi: |
10.3389/fphar.2020.01196 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ046273247 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ046273247 | ||
| 003 | DE-627 | ||
| 005 | 20230308104712.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fphar.2020.01196 |2 doi | |
| 035 | |a (DE-627)DOAJ046273247 | ||
| 035 | |a (DE-599)DOAJ9b75a22ff1ec4dc28c4c1441aa5370c3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RM1-950 | |
| 100 | 0 | |a Malak Kaddoura |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 Therapeutic Options Under Investigation |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Since its emergence in China in December 2019, COVID-19 has quickly spread around the globe causing a pandemic. Vaccination or the development of herd immunity seems the only way to slow down the spread of the virus; however, both are not achievable in the near future. Therefore, effective treatments to mitigate the burden of this pandemic and reduce mortality rates are urgently needed. Preclinical and clinical studies of potential antiviral and immunomodulatory compounds and molecules to identify safe and efficacious therapeutics for COVID-19 are ongoing. Two compounds, remdesivir, and dexamethasone have been so far shown to reduce COVID-19–associated death. Here, we provide a review of the potential therapeutic agents being considered for the treatment and management of COVID-19 patients. | ||
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a antivirals | |
| 650 | 4 | |a adjunctive therapy | |
| 650 | 4 | |a therapeutics | |
| 653 | 0 | |a Therapeutics. Pharmacology | |
| 700 | 0 | |a Malak Kaddoura |e verfasserin |4 aut | |
| 700 | 0 | |a Malak AlIbrahim |e verfasserin |4 aut | |
| 700 | 0 | |a Malak AlIbrahim |e verfasserin |4 aut | |
| 700 | 0 | |a Ghina Hijazi |e verfasserin |4 aut | |
| 700 | 0 | |a Ghina Hijazi |e verfasserin |4 aut | |
| 700 | 0 | |a Nadia Soudani |e verfasserin |4 aut | |
| 700 | 0 | |a Nadia Soudani |e verfasserin |4 aut | |
| 700 | 0 | |a Amani Audi |e verfasserin |4 aut | |
| 700 | 0 | |a Amani Audi |e verfasserin |4 aut | |
| 700 | 0 | |a Habib Alkalamouni |e verfasserin |4 aut | |
| 700 | 0 | |a Habib Alkalamouni |e verfasserin |4 aut | |
| 700 | 0 | |a Salame Haddad |e verfasserin |4 aut | |
| 700 | 0 | |a Salame Haddad |e verfasserin |4 aut | |
| 700 | 0 | |a Ali Eid |e verfasserin |4 aut | |
| 700 | 0 | |a Hassan Zaraket |e verfasserin |4 aut | |
| 700 | 0 | |a Hassan Zaraket |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Frontiers in Pharmacology |d Frontiers Media S.A., 2010 |g 11(2020) |w (DE-627)DOAJ000099732 |x 16639812 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2020 |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fphar.2020.01196 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/9b75a22ff1ec4dc28c4c1441aa5370c3 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.frontiersin.org/article/10.3389/fphar.2020.01196/full |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1663-9812 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2020 | ||